文献速递关节外科骨肿瘤

初次全髋关节置换术患者的内脏器官恶性肿瘤:阿司匹林预防是否有作用?

Visceral Organ Malignancy in Patients Undergoing Primary Total Hip Arthroplasty: Is There a Role for Aspirin Prophylaxis?
PubMed 文献 · J Arthroplasty · 2025-06-03

本研究利用全国数据库纳入2012至2022年间初次全髋关节置换术前1年内诊断内脏器官恶性肿瘤的患者,经倾向评分1:1匹配后比较阿司匹林组(n=2,342)与非阿司匹林抗凝药组(n=2,342)的90天并发症。阿司匹林组深静脉血栓、肺栓塞及假体周围感染发生率均显著低于非阿司匹林组。作者认为阿司匹林是此类患者安全有效的静脉血栓栓塞预防方法。

要点

  • 匹配后阿司匹林组深静脉血栓1.2% vs 非阿司匹林组2.0%(OR 0.58,P=0.027)。
  • 阿司匹林组肺栓塞0.5% vs 非阿司匹林组1.1%(OR 0.44,P=0.023)。
  • 阿司匹林组假体周围感染0.8% vs 非阿司匹林组1.8%(OR 0.42,P=0.003)。

核心结论

  • 作者认为,对于活动性内脏器官恶性肿瘤接受初次全髋关节置换术的患者,阿司匹林似乎是安全有效的静脉血栓栓塞预防方法。

研究设计与样本

  • 本研究使用全国数据库识别2012年至2022年间接受初次全髋关节置换术的患者。
  • 仅纳入初次全髋关节置换术前1年内有内脏器官恶性肿瘤诊断代码的患者。
  • 根据人口学数据、内科合并症和术前抗凝使用情况,将因癌症而处方阿司匹林进行血栓预防的初次全髋关节置换术患者(n=2,342)与非阿司匹林药物患者(n=2,342)进行1:1倾向评分匹配。
  • 分析共纳入4,684例匹配的初次全髋关节置换术患者。

主要发现

  • 与非阿司匹林组相比,阿司匹林组发生深静脉血栓的比值显著更低(1.2% vs 2.0%;OR 0.58 [0.4至0.9];P=0.027)。
  • 与非阿司匹林组相比,阿司匹林组发生肺栓塞的比值显著更低(0.5% vs 1.1%;OR 0.44 [0.2至0.9];P=0.023)。
  • 与非阿司匹林组相比,处方阿司匹林的患者发生假体周围感染的可能性显著更低(0.8% vs 1.8%;OR 0.42 [0.2至0.7];P=0.003)。

关键数值与推荐

  • 纳入标准:初次全髋关节置换术前1年内有内脏器官恶性肿瘤诊断代码。
  • 主要比较指标:处方阿司匹林仅用 versus 其他类型化学预防的患者90天内科和外科并发症的比值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although aspirin has become the prophylactic agent of choice for venous thromboembolism prevention in low-risk patients undergoing primary total hip arthroplasty (THA), there remains a paucity of data in the literature on the efficacy of aspirin as a mode of chemoprophylaxis in patients who had recent cancer. The purpose of this study was to determine the efficacy of aspirin versus other anticoagulant medications in primary THA patients who were diagnosed with a visceral organ malignancy within 1 year before their arthroplasty procedure. METHODS: This study used a national database to identify patients who underwent primary THA between 2012 and 2022. Only patients who had a diagnosis code for a visceral organ malignancy within 1 year before their primary THA were included. Using demographic data, medical comorbidities, and preoperative anticoagulation use, primary THA patients who had cancer who were prescribed aspirin for thromboprophylaxis (n = 2,342) were propensity score matched on a 1:1 basis to those who were on non-aspirin medications (n = 2,342). The odds of developing 90-day medical and surgical complications were assessed and compared between patients prescribed aspirin only versus other types of chemoprophylaxis. There were 4,684 matched patients undergoing primary THA included in the analysis. RESULTS: Patients in the aspirin-group had significantly lower odds of developing deep vein thrombosis (1.2 versus 2.0%; odds ratio [OR] 0.58 [0.4 to 0.9]; P = 0.027) and pulmonary embolism (0.5 versus 1.1%; OR 0.44 [0.2 to 0.9]; P = 0.023), when compared to their counterparts in the non-aspirin group. Furthermore, patients prescribed aspirin were significantly less likely to develop periprosthetic joint infection (0.8 versus 1.8%; OR 0.42 [0.2 to 0.7]; P = 0.003). CONCLUSIONS: Based on these findings, it appears that aspirin is a safe and effective method of venous thromboembolism prophylaxis in patients with an active visceral organ cancer that are undergoing primary THA.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Tarabichi S, Verhey JT, Brinkman JC, et al. Visceral Organ Malignancy in Patients Undergoing Primary Total Hip Arthroplasty: Is There a Role for Aspirin Prophylaxis? J Arthroplasty. 2025. PMID: 40473051. doi:10.1016/j.arth.2025.05.105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。